Novartis AG Has $10 Billion to Spend on M&As, Just Not on Onyx Pharmaceuticals, Inc.

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis AG (NOVN) Chairman Joerg Reinhardt said a $10 billion purchase is possible as the drugmaker reviews its business, including units focused on animal health and vaccines.

“We will also start next week to look at our portfolio based on strategic perspectives going forward,” Reinhardt said in an interview at the company’s Basel, Switzerland, headquarters today. Bolt-on deals are attractive, and “I don’t think a $10 billion acquisition is out of reach.”

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC